{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:58:28Z","timestamp":1785571108668,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12098-026-06205-w","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:51:48Z","timestamp":1783302708000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Enzyme Replacement Therapy on Patients with Late Onset Pompe Disease \u2013 Real World Data from a Developing Country"],"prefix":"10.1007","volume":"93","author":[{"given":"Swasti","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Bijarnia-Mahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Nampoothiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Muranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"VH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeva","family":"GN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanya","family":"Yesodharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerana","family":"Modani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-6147","authenticated-orcid":false,"given":"Ratna Dua","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"6205_CR1","unstructured":"Sperry E, Leslie N, Berry L, Pena L. Pompe Disease. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993\u20132025. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1261\/. Accessed 18 Nov 2025."},{"key":"6205_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/biom13091279","volume":"13","author":"B Labella","year":"2023","unstructured":"Labella B, Cotti Piccinelli S, Risi B, et al. A comprehensive update on late-onset Pompe disease. Biomolecules. 2023;13:1279.","journal-title":"Biomolecules"},{"key":"6205_CR3","doi-asserted-by":"publisher","first-page":"501933","DOI":"10.1016\/j.nrl.2025.501933","volume":"41","author":"C Dom\u00ednguez-Gonz\u00e1lez","year":"2026","unstructured":"Dom\u00ednguez-Gonz\u00e1lez C, Barba Romero M\u00c1, Caballero Eraso C, et al. Recommendations for the diagnosis, treatment, and follow-up of late-onset pompe disease. Neurologia. 2026;41:501933.","journal-title":"Neurologia"},{"key":"6205_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120:163\u201372.","journal-title":"Mol Genet Metab"},{"key":"6205_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, et al; European Pompe Consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017;24:768\u2013831.","journal-title":"Eur J Neurol"},{"key":"6205_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.nmd.2021.02.013","volume":"31","author":"RD Puri","year":"2021","unstructured":"Puri RD, Setia N, N V, et al. Late onset Pompe disease in India \u2013 beyond the Caucasian phenotype. Neuromuscul Disord. 2021;31:431\u201341.","journal-title":"Neuromuscul Disord"},{"key":"6205_CR7","doi-asserted-by":"publisher","first-page":"1309146","DOI":"10.3389\/fgene.2024.1309146","volume":"15","author":"C Carter","year":"2024","unstructured":"Carter C, Boggs T, Case LE, Kishnani P. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa. Front Genet. 2024;15:1309146.","journal-title":"Front Genet"},{"key":"6205_CR8","unstructured":"Sanofi-Aventis U.S. LLC. Nexviazyme (Avalglucosidase Alfa-Ngpt) Prescribing information [Internet]. Cambridge (MA): Sanofi-Aventis U.S. LLC; 2023. Available at: https:\/\/products.sanofi.us\/nexviazyme\/nexviazyme.pdf. Accessed 24 Mar 2026."},{"key":"6205_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362:1396\u2013406.","journal-title":"N Engl J Med"},{"key":"6205_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT, et al; AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45:319\u201333.","journal-title":"Muscle Nerve"},{"key":"6205_CR11","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1212\/WNL.0000000000201333","volume":"100","author":"T Maulet","year":"2023","unstructured":"Maulet T, Bonnyaud C, Weill C, Lafor\u00eat P, Cattagni T. Motor function characteristics of adults with late-onset Pompe disease: a systematic scoping review. Neurology. 2023;100:e72\u201383.","journal-title":"Neurology"},{"key":"6205_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-021-10526-5","volume":"269","author":"B Sarah","year":"2022","unstructured":"Sarah B, Giovanna B, Emanuela K, Nadi N, Jos\u00e8 V, Alberto P. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. J Neurol. 2022;269:733\u201341.","journal-title":"J Neurol"},{"key":"6205_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/jimd.12027","volume":"42","author":"J Milverton","year":"2019","unstructured":"Milverton J, Newton S, Merlin T. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis. 2019;42:57\u201365.","journal-title":"J Inherit Metab Dis"},{"key":"6205_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","volume":"17","author":"W M\u00fcller-Felber","year":"2007","unstructured":"M\u00fcller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17:698\u2013706.","journal-title":"Neuromuscul Disord"},{"key":"6205_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D G\u00fcng\u00f6r","year":"2011","unstructured":"G\u00fcng\u00f6r D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.","journal-title":"Orphanet J Rare Dis"},{"key":"6205_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","volume":"252","author":"LP Winkel","year":"2005","unstructured":"Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases. J Neurol. 2005;252:875\u201384.","journal-title":"J Neurol"},{"key":"6205_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2147\/TCRM.S362871","volume":"19","author":"L El Haddad","year":"2023","unstructured":"El Haddad L, Khan M, Soufny R, et al. Monitoring and management of respiratory function in pompe disease: current perspectives. Ther Clin Risk Manag. 2023;19:713\u201329.","journal-title":"Ther Clin Risk Manag"},{"key":"6205_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nmd.2019.06.011","volume":"29","author":"J Spiesshoefer","year":"2019","unstructured":"Spiesshoefer J, Henke C, Kabitz HJ, et al. The nature of respiratory muscle weakness in patients with late-onset Pompe disease. Neuromuscul Disord. 2019;29:618\u201327.","journal-title":"Neuromuscul Disord"},{"key":"6205_CR19","first-page":"199","volume":"9","author":"BR Brenn","year":"2017","unstructured":"Brenn BR, Theroux MT, Shah SA, Mackenzie WG, Heinle R, Scavina MT. Critical airway stenosis in an adolescent male with Pompe disease and thoracic lordosis: a case report. Case Rep. 2017;9:199\u2013203.","journal-title":"Case Rep"},{"key":"6205_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.nmd.2011.06.748","volume":"21","author":"RY Carlier","year":"2011","unstructured":"Carlier RY, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul Disord. 2011;21:791\u20139.","journal-title":"Neuromuscul Disord"},{"key":"6205_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nmd.2022.01.001","volume":"32","author":"M Winkler","year":"2022","unstructured":"Winkler M, von Landenberg C, Kuchenbecker K, Reimann J, Kornblum C. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease. Neuromuscul Disord. 2022;32:195\u2013205.","journal-title":"Neuromuscul Disord"},{"key":"6205_CR22","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s00415-014-7402-z","volume":"261","author":"T Hundsberger","year":"2014","unstructured":"Hundsberger T, R\u00f6sler KM, Findling O. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol. 2014;261:1684\u201390.","journal-title":"J Neurol"},{"key":"6205_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00408-013-9489-x","volume":"191","author":"A Vianello","year":"2013","unstructured":"Vianello A, Semplicini C, Paladini L, et al. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung. 2013;191:537\u201344.","journal-title":"Lung"},{"key":"6205_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis. 2013;8:160.","journal-title":"Orphanet J Rare Dis"},{"key":"6205_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1183\/09031936.05.00020005","volume":"26","author":"N Pellegrini","year":"2005","unstructured":"Pellegrini N, Lafor\u00eat P, Orlikowski D, et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe\u2019s disease. Eur Respir J. 2005;26:1024\u201331.","journal-title":"Eur Respir J"},{"key":"6205_CR26","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1002\/ajmg.a.36227","volume":"161a","author":"S Kansagra","year":"2013","unstructured":"Kansagra S, Austin S, DeArmey S, Kishnani PS, Kravitz RM. Polysomnographic findings in infantile Pompe disease. Am J Med Genet A. 2013;161a:3196\u2013200.","journal-title":"Am J Med Genet A"},{"key":"6205_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1212\/WNL.57.7.1290","volume":"57","author":"U Mellies","year":"2001","unstructured":"Mellies U, Ragette R, Schwake C, Baethmann M, Voit T, Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology. 2001;57:1290\u20135.","journal-title":"Neurology"},{"key":"6205_CR28","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","volume":"99","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie MM, Barohn RJ, Byrne B, et al; NEO-EXT Investigators. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology. 2022;99:e536\u201348.","journal-title":"Neurology"},{"key":"6205_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12883-015-0412-3","volume":"15","author":"F Al Jasmi","year":"2015","unstructured":"Al Jasmi F, Al Jumah M, Alqarni F, et al; MENA Pompe Working Group. Diagnosis and treatment of late-onset pompe disease in the middle east and North Africa region: consensus recommendations from an expert group. BMC Neurol. 2015;15:205.","journal-title":"BMC Neurol"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-026-06205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-026-06205-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-026-06205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:39:04Z","timestamp":1785569944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-026-06205-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":29,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6205"],"URL":"https:\/\/doi.org\/10.1007\/s12098-026-06205-w","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Priya S. Kishnani has received research\/grant support from Sanofi Genzyme and Amicus Therapeutics; has received consulting fees and honoraria from Sanofi Genzyme, Amicus Therapeutics, Denali, Regeneron, Shionogi and Asklepios Biopharmaceutical, Inc. (AskBio). Priya S. Kishnani is a member of the Pompe and Gaucher Disease Registry Advisory Board for Sanofi Genzyme, and Pompe Disease Advisory Board for Amicus Therapeutics. Priya S. Kishnani has held equity in Asklepios Biopharmaceuticals, and may receive milestone payments related to that equity in the future.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}